rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGCAGGCATGCAGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	18	0.00241578311636022		52	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	12	5	23	34	50	46	55			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-06	TCRBV09-01	TCRBD01-01*01	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGCCAAACAGCTTTGTACTTCTGTGCCAGCAGCGTAGACGGGGACTAGCGGGAGGGCCGGAGACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	19	0.0025499932894913436		59	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	0	0	5	3	6	22	38	57	41	63			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01*02	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGGACAGGGATTTTGTACAATGAGCAGTTCTTCGGGCCA	CASSQGTGILYNEQFF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	1	3	4	0	6	29	-1	53	45	59													Vb 16	CASSQGTGILYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACCTACAGGGAGGGAGGCGACAGATACGCAGTATTTTGGCCCA	CASSQPTGREATDTQYF	In	VDJ	1	46	0.006173667964031674	0.007680748038069795	51	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	9	0	3	6	5	29	44	57	50	62													Vb 16	CASSQPTGREATDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCATCCCGCCGGGAGCAGTACTTCGGGCCG	CASSPSRREQYF	In	VDJ	1	57	0.00764997986847403	0.009517448655869093	36	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	8	5	7	8	0	29	42	-1	50	53						01,02							Vb 16	CASSPSRREQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGAAACGGGCCTGAGAAGAGAAAGAGACCCAGTACTTCGGGCCA	CASSRKRA*EEKETQYF	Stop	VDJ	1	59	0.007918400214736276		51	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-05	01	4	8	0	3	6	11	29	42	52	48	63				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSRKRA*EEKETQYF+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01		TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTTACTTTGGCGGAGGCACAGATACGCAGTATTTTGGCCCA	CASSYFGGGTDTQYF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	7	5	1	8	2	24	35	47	43	49						01,02								CASSYFGGGTDTQYF+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCATCTCGCGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASISRSYNEQFF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	39	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	10	7	5	1	7	0	24	31	-1	38	42						01,02								CASISRSYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGTCAGCAGTGAAGCGCCAGGCGCAGATACGCAGTATTTTGGCCCA	CVSSEAPGADTQYF	In	VDJ	1	18	0.00241578311636022	0.003005510101853398	42	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-03	01	6	4	4	4	8	2	24	35	47	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CVSSEAPGADTQYF+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01		TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCACCAGCCTCCACCCCGGGGGCGACGAGCAGTACTTCGGGCCA	CASTSLHPGGDEQYF	In	VDJ	1	19	0.0025499932894913436	0.003172482885289698	45	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-05	01	10	6	0	11	17	6	24	31	54	48	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTSLHPGGDEQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01		TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCTCGAAGGGACGGGGGCTTTCACTTACGAGCAGTACTTCGGGCCG	CASSLEGTGAFTYEQYF	In	VDJ	1	20	0.002684203462622467	0.0033394556687259976	51	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-07	01	5	6	0	4	11	7	24	36	53	47	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGTGAFTYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01		TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTCCGCCCCCGGGACATCCTACGAGCAGTACTTCGGGCCG	CASSSAPGTSYEQYF	In	VDJ	1	21	0.00281841363575359	0.0035064284521622974	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	6	1	9	0	24	36	-1	45	51														CASSSAPGTSYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGTCCTCGGCTGGGATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	27	0.00362367467454033		46	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-01	01	6	0	8	0	11	0	24	35	-1	46	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGTAGCCAGTCCCCAACTCTCCCAGATACGCAGTATTTTGGCCCA	CASSQSPTLPDTQYF	In	VDJ	1	28	0.0037578848476714534	0.0046752379362163966	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	10	5	7	4	1	16	24	31	36	32	52						01,02								CASSQSPTLPDTQYF+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCCAGACGGCTCGGGGAAGTAGCTGGCTACACCTTCGGTTCG	CASSPRRLGEVAGYTF	In	VDJ	1	29	0.003892095020802577	0.004842210719652696	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	8	3	7	11	7	24	36	52	47	59														CASSPRRLGEVAGYTF+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGGCCAGAGGGCCGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CGQRAGNTGELFF	In	VDJ	1	32	0.004294725540195947	0.005343129069961597	39	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	13	11	0	1	4	4	24	28	37	32	41														CGQRAGNTGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTTCAGCTAACTATGGCTACACCTTCGGTTCG	CASSSANYGYTF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	36	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	5	0	2	0	24	35	-1	37	40														CASSSANYGYTF+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGGACTAGCGGGGGGCGGGGAGACCCAGTACTTCGGGCCA	CASSGLAGGGETQYF	In	VDJ	1	44	0.0059052476177694265	0.0073468024711971945	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	1	1	5	1	4	24	35	50	36	54														CASSGLAGGGETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGAGCCCCCGGGACTAGCCGTAACAATGAGCAGTTCTTCGGGCCA	CASRAPGTSRNNEQFF	In	VDJ	1	50	0.006710508656556167	0.008348639171814994	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	7	5	7	4	24	35	51	42	55						01,02								CASRAPGTSRNNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGCAGCCAGCGGCAGGGGTGAAGCTTTCTTTGGACAA	CASSAASGRGEAFF	In	VDJ	1	68	0.009126291772916387	0.011354149273668393	42	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	2	7	11	0	24	36	-1	47	53														CASSAASGRGEAFF+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCAAGCAAGAACAGAGACCCAGTACTTCGGGCCA	CASSQARTETQYF	In	VDJ	2	87	0.01167628506240773	0.01452663215895809	39	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-05	01	0	2	8	4	2	2	24	41	45	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQARTETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01		TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCCTCTGGGGGTCGGGCCGGGGAGCTGTTTTTTGGAGAA	CASSPSGGRAGELFF	In	VDJ	2	88	0.011810495235538853	0.014693604942394389	45	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-02	01	5	6	1	6	6	5	24	36	47	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSGGRAGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01		TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCAGCAATCCAGGGGGGGAGGAGAGACCCAGTACTTCGGGCCA	CASSQQSRGGGETQYF	In	VDJ	3	121	0.016239430948865922	0.020203706795792285	48	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-05	01	5	4	1	4	8	5	24	36	51	44	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQQSRGGGETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01		TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTAAGAGGGGCTGAGACTGAAGCTTTCTTTGGACAA	CASSLRGAETEAFF	In	VDJ	7	321	0.04308146557509059	0.053598263483052265	42	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-01	01	5	5	2	5	5	5	24	36	46	41	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRGAETEAFF+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCCCCCGTTAGGCCTGCGGGAGATAAGAGACCCAGTACTTCGGGCCA	CASSPR*ACGR*ETQYF	Stop	VDJ	1	17	0.0022815729432290968		51	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	7	2	3	13	2	18	30	50	43	52														CASSPR*ACGR*ETQYF+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01	TCRBD02-01*02	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCCCCCGGGCCCTACTCTCTGGAAACACCATATATTTTGGAGAG	CASSPRALLSGNTIYF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	48	TCRBV07	TCRBV07-05	01				TCRBJ01	TCRBJ01-03	01	4	8	0	0	4	6	19	31	39	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRALLSGNTIYF+TCRBV07-05+TCRBJ01-03	TCRBV07-05*01		TCRBJ01-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGGTGGAACTTCACCCCTCCACTTTGGGAAC	CAWSGGTSPLHF	In	VDJ	1	29	0.003892095020802577	0.004842210719652696	36	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-06	01	1	1	8	9	2	2	26	39	44	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSGGTSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*02		TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAAGGGACAGGCCATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	31	0.004160515367064824		47	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	4	0	2	3	26	40	50	42	53													Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGTTACAGGGGGCCTAATCTTTACGCAGTATTTTGGCCCA	CAWVTGGLIFTQYF	In	VDJ	1	34	0.0045631458864581935	0.005677074636834196	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	0	8	3	8	26	35	47	38	55													Vb 20	CAWVTGGLIFTQYF+TCRBV30-01+TCRBJ02-03	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAATGGGGGGGTACTTAATTCACCCCTCCACTTTGGGAAC	CAWNGGVLNSPLHF	In	VDJ	1	36	0.00483156623272044	0.006011020203706796	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	4	9	0	6	2	4	26	36	45	38	49													Vb 20	CAWNGGVLNSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*01	TCRBD02-01*01	TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCAGTAGTTCAGGGCGCTCGGGGACTGAAGCTTTCTTTGGACAA	CASSSGRSGTEAFF	In	VDJ	1	38	0.005099986578982687	0.006344965770579396	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	8	4	3	5	7	9	26	32	44	39	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CASSSGRSGTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGTCGGACAGGGGCTATGGCTACACCTTCGGTTCG	CAWSDRGYGYTF	In	VDJ	1	55	0.007381559522211784	0.009183503088996493	36	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	2	4	2	0	26	35	-1	37	46													Vb 20	CAWSDRGYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTCCGTCCTCGGCGGGAGGGGAGAGACCCAGTACTTCGGGCCA	CASVLGGRGETQYF	In	VDJ	1	57	0.00764997986847403	0.009517448655869093	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	7	0	4	9	1	26	33	51	42	52													Vb 20	CASVLGGRGETQYF+TCRBV30-01+TCRBJ02-05	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGAATCGAGGGCCATGAAGCTTTCTTTGGACAA	CAWRIEGHEAFF	In	VDJ	2	88	0.011810495235538853	0.014693604942394389	36	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	11	0	7	4	3	26	37	46	41	49			unresolved										Vb 20	CAWRIEGHEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02	TCRBD02-01*02	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGTTGGGGAAGCTTTCTTTGGACAA	CAWSVVGEAFF	In	VDJ	2	92	0.012347335928063348	0.01536149607613959	33	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	0	0	9	8	4	0	26	40	-1	44	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVVGEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCACTCCCGAGGGTCGATGAGCAGTTCTTCGGGCCA	CASSLALPRVDEQFF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	11	0	8	7	3	19	35	47	42	50													Vb 5.1	CASSLALPRVDEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCGGCCCTTTATCTTTGCCAGCAGCTTAGTACATCACAACGGCGCCGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	22	0.0029526238088847133		46	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-04	01	13	3	6	8	12	13	19	22	37	34	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	X+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01		TCRBJ01-04*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCAAGGTGGGGACTCCCTCGGATGGCCCCAGCATTTTGGTGAT	CASSQGGDSLGWPQHF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	4	0	10	9	7	10	19	31	44	38	54						01,02							Vb 5.1	CASSQGGDSLGWPQHF+TCRBV05-01+TCRBJ01-05	TCRBV05-01*01	TCRBD02-01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAGGCGTCACCCCAGGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	20	0.002684203462622467		41	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	4	3	5	11	0	25	35	-1	46	51													Vb 3	X+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTTAACATTAGGAGCGGGAGCCCCCCCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	16	0.0021473627700979736		56	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	6	2	2	8	6	18	33	49	41	55														X+TCRBV12-02+TCRBJ02-03	TCRBV12-02*01	TCRBD02-01*02	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGTAGTATCGTGCGAACTGGTGGTGAGCAGTTCTTCGGGCCA	CASSIVRTGGEQFF	In	VDJ	1	59	0.007918400214736276	0.009851394222741693	42	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	3	10	9	12	5	18	27	42	39	47						01,02								CASSIVRTGGEQFF+TCRBV12-02+TCRBJ02-01	TCRBV12-02*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGGCCAGAGGACAATCAGCCCCAGCATTTTGGTGAT	CASRPEDNQPQHF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	39	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	11	1	3	4	1	22	33	41	37	42														CASRPEDNQPQHF+TCRBV07-01+TCRBJ01-05	TCRBV07-01*01	TCRBD02-01*02	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGCCCAAGTCTAGCGGGGGGCAATGAGCAGTTCTTCGGGCCA	CASSPSLAGGNEQFF	In	VDJ	1	19	0.0025499932894913436	0.003172482885289698	45	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	4	1	6	7	0	23	34	-1	41	52													Vb 12	CASSPSLAGGNEQFF+TCRBV10-02+TCRBJ02-01	TCRBV10-02*01	TCRBD02-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGGGGCAGCGGACGAGCAGTACTTCGGGCCG	CASSGAADEQYF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	36	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	6	5	5	4	0	23	36	-1	40	45						01,02							Vb 12	CASSGAADEQYF+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01	TCRBD02-01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTTGGACAGGGAGATACTCCTACGAGCAGTACTTCGGGCCG	CASSWTGRYSYEQYF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	45	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	3	0	1	5	23	35	44	36	49													Vb 12	CASSWTGRYSYEQYF+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCCCAGACATCTGTGTATTTCTGCGCCAGCATTTTCCTTTACCCTTCGGGGGCAGCACTCTCTGGAAACACCATATATTTTGGAGAG	CASIFLYPSGAALSGNTIYF	In	VDJ	1	51	0.006844718829687291	0.008515611955251294	60	TCRBV10	TCRBV10-02	01				TCRBJ01	TCRBJ01-03	01	7	6	0	0	16	6	21	31	53	47	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASIFLYPSGAALSGNTIYF+TCRBV10-02+TCRBJ01-03	TCRBV10-02*01		TCRBJ01-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCAGAGGACAGGGGAACACTGAAGCTTTCTTTGGACAA	CAIRGQGNTEAFF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	39	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	3	1	1	0	24	35	-1	36	44													Vb 12	CAIRGQGNTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACTAGGGGAAATATATGGCTACACCTTCGGTTCG	CASSILGEIYGYTF	In	VDJ	1	18	0.00241578311636022	0.003005510101853398	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	5	2	5	2	5	27	42	49	44	54			01,02										Vb 17	CASSILGEIYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGATTTCTTAGGAGGCTCAAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSRIS*EAQSSYEQYF	Stop	VDJ	1	30	0.0040263051939337		54	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	10	1	0	10	7	27	40	55	50	62			01,02										Vb 17	CASSRIS*EAQSSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCTACAGACAGGGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	41	0.005502617098376057		43	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	3	3	6	0	27	40	-1	46	53			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGACCCGGGACAGGTCGGAAGGGTGGCTACACCTTCGGTTCG	CARPGTGRKGGYTF	In	VDJ	1	44	0.0059052476177694265	0.0073468024711971945	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	0	4	7	4	9	27	35	47	39	56			01,02										Vb 17	CARPGTGRKGGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTCGCGGGCCTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSVAGLSGANVLTF	In	VDJ	1	48	0.00644208831029392	0.008014693604942395	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	5	7	4	0	3	3	27	39	47	42	50			01,02			01,02							Vb 17	CASSVAGLSGANVLTF+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD02-01	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAGGGGATCCCACCGGCCGGGGAGCTGTTTTTTGGAGAA	CASKGIPPAGELFF	In	VDJ	1	57	0.00764997986847403	0.009517448655869093	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	5	2	6	0	10	27	-1	42	37	52			01,02										Vb 17	CASKGIPPAGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACGGATCGAATCGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	63	0.008455240907260771		47	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	4	1	8	4	1	14	27	40	44	41	58			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACAGGGAAGAACTGAAGCTTTCTTTGGACAA	CASSIQGRTEAFF	In	VDJ	1	70	0.009394712119178633	0.011688094840540992	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	3	5	0	4	27	-1	47	42	51			01,02										Vb 17	CASSIQGRTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATAGAAATACAGGGCATTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	14	0.0018789424238357267		47	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	3	3	6	5	3	23	40	51	45	54													Vb 11	X+TCRBV25-01+TCRBJ01-05	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTTAGCGTGGAAAACTGGGAAAGACCTATGGCTACACCTTCGGTTCG	CASS*RGKLGKTYGYTF	Stop	VDJ	1	21	0.00281841363575359		51	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	5	6	4	0	18	23	-1	40	35	58						01,02							Vb 11	CASS*RGKLGKTYGYTF+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01	TCRBD02-01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GTTTGGTSMSMSMSASMYMTCTGTACCWCTGTGGCAGTTGCGACTCTATAGCCACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	2	79	0.010602603677358744		52	TCRBV08	TCRBV08-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	6	2	10	5	4	16	22	30	38	34	54						01,02								X+TCRBV08-02+TCRBJ02-06	TCRBV08-02*01	TCRBD02-01	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCRGCCMTSTATCKCTGTGCCGTGGCGTCGGGGGGTGAATAGTGGCTACACCTTCGGTTCG		Out	VDJ	1	14	0.0018789424238357267		40	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	10	8	1	7	7	7	19	25	39	32	46	TCRBV05,TCRBV07													X+X+TCRBJ01-02	unresolved	TCRBD02-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGACCCACCTCGGGGTACCAAGAGACCCAGTACTTCGGGCCA	CASRPTSGYQETQYF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	8	3	0	8	1	22	33	46	41	47	TCRBV07,TCRBV11													CASRPTSGYQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCTCCCGGACTAGCGGGACTCGGAATGAGCAGCTCTTCGGGCCA	CASSSRTSGTRNEQLF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	48	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	1	3	17	5	15	26	37	54	42	69		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSSRTSGTRNEQLF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACAGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CSATGGNQPQHF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	4	2	2	0	0	26	-1	-1	36	42		TCRBV20-01,TCRBV20-or09_02												CSATGGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCGGACAGGGAGTATGGCTACACCTTCGGTTCG	CSARDPDREYGYTF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	3	5	3	2	26	40	51	43	53		TCRBV20-01,TCRBV20-or09_02												CSARDPDREYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCTTATGGGCGGATAATTACAATGAGCAGTTCTTCGGGCCA	CASSLWADNYNEQFF	In	VDJ	1	16	0.0021473627700979736	0.0026715645349807983	45	unresolved						TCRBJ02	TCRBJ02-01	01	2	8	0	4	1	7	26	41	46	42	53	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLWADNYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTACAGGCCCTAAGGCCTACGAGCAGTACTTCGGGCCG	CASSTGPKAYEQYF	In	VDJ	1	16	0.0021473627700979736	0.0026715645349807983	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	4	2	0	8	26	-1	43	38	51		TCRBV12-03,TCRBV12-04												CASSTGPKAYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGCGTATGGGGGGCTGGGGACTGAAGCTTTCTTTGGACAA	CASAYGGLGTEAFF	In	VDJ	1	16	0.0021473627700979736	0.0026715645349807983	42	TCRBV24						TCRBJ01	TCRBJ01-01	01	11	6	0	5	9	5	24	31	46	40	51		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASAYGGLGTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCGGGCAGGGGTATATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	16	0.0021473627700979736		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	2	0	3	4	18	35	44	38	48	TCRBV07,TCRBV11													X+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGTCCTTCAAGGGGGCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	16	0.0021473627700979736		41	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	5	1	6	7	0	19	30	-1	37	43		TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ02-02	TCRBV05	TCRBD01-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTACCTGGGCAGGGGTCGGGGAGACCCAGTACTTCGGGCCA	CASSTWAGVGETQYF	In	VDJ	1	17	0.0022815729432290968	0.002838537318417098	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	2	5	7	5	36	48	61	55	66	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASSTWAGVGETQYF+X+TCRBJ02-05		TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACACCCGGGTGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	17	0.0022815729432290968		40	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	8	4	1	4	2	26	36	44	40	46		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTGTTGGGACAGGGTGAAGCTTTCTTTGGACAA	CASSLLGQGEAFF	In	VDJ	1	18	0.00241578311636022	0.003005510101853398	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	0	3	7	3	0	22	36	-1	39	48		TCRBV12-03,TCRBV12-04												CASSLLGQGEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATGACCTTCTCGGGGAGCTGTTTTTTGGAGAA	CASSHDLLGELFF	In	VDJ	1	19	0.0025499932894913436	0.003172482885289698	39	TCRBV03						TCRBJ02	TCRBJ02-02	01	3	2	7	7	1	5	26	40	44	41	49		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHDLLGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCGACGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CATSATGGNQPQHF	In	VDJ	1	21	0.00281841363575359	0.0035064284521622974	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	8	2	2	3	0	24	37	-1	40	46		TCRBV24-01,TCRBV24-or09_02												CATSATGGNQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCGGAGCGGGGGCTGCCTACGAGCAGTACTTCGGGCCG	CASGAGAAYEQYF	In	VDJ	1	21	0.00281841363575359	0.0035064284521622974	39	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	11	6	2	2	4	3	24	31	43	35	46	TCRBV24,TCRBV27													CASGAGAAYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATCGTCCAGGAAACTATGGCTACACCTTCGGTTCG	CASSHRPGNYGYTF	In	VDJ	1	22	0.0029526238088847133	0.0036734012355985972	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	4	2	5	1	26	40	49	45	50		TCRBV03-01,TCRBV03-02												CASSHRPGNYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGGGAGGACAGTCCCTACGAGCAGTACTTCGGGCCG	CSAREDSPYEQYF	In	VDJ	1	23	0.003086833982015837	0.0038403740190348975	39	TCRBV20						TCRBJ02	TCRBJ02-07	01	6	1	5	2	6	2	26	34	46	40	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAREDSPYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTTTAGCGGAGACTACAATGAGCAGTTCTTCGGGCCA	CSAFSGDYNEQFF	In	VDJ	1	23	0.003086833982015837	0.0038403740190348975	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	5	5	3	3	3	26	34	43	37	46		TCRBV20-01,TCRBV20-or09_02				01,02								CSAFSGDYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAAGGCAGAAGCTAACTATGGCTACACCTTCGGTTCG	CSARDKAEANYGYTF	In	VDJ	1	23	0.003086833982015837	0.0038403740190348975	45	TCRBV20						TCRBJ01	TCRBJ01-02	01	0	4	5	0	5	3	26	40	48	45	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDKAEANYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTCCAAAGGACCAGGGGGAGTGACTGAAGCTTTCTTTGGACAA	CSASKGPGGVTEAFF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	1	5	11	4	26	34	52	45	56		TCRBV20-01,TCRBV20-or09_02												CSASKGPGGVTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCCTAGCGGGATCACAGATACGCAGTATTTTGGCCCA	CSASPSGITDTQYF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	3	2	2	1	26	37	48	39	49		TCRBV20-01,TCRBV20-or09_02												CSASPSGITDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCWMCCAGACAKCTSTKTACTTSTGTGCCAGCAGTTTACTGGCCGGGCCAGGAGCTAACTATGGCTACACCTTCGGTTCG	CASSLLAGPGANYGYTF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	51	unresolved						TCRBJ01	TCRBJ01-02	01	4	4	4	0	12	2	23	36	52	48	54	TCRBV06,TCRBV24			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLLAGPGANYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCGGCCRTGTATSKCTGTGCCAGCAGCTTAGTTCAGGAAACTAGCGGGGGGGCGACTGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLVQETSGGATANTGELFF	In	VDJ	1	26	0.003489464501409207	0.004341292369343797	66	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	3	0	0	8	6	15	31	52	39	58	TCRBV07,TCRBV11													CASSLVQETSGGATANTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCTCGATGGCGGCTGCCGGGGAGCTGTTTTTTGGAGAA	CASSSMAAAGELFF	In	VDJ	1	27	0.00362367467454033	0.004508265152780097	42	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	7	5	6	7	3	26	37	48	44	51		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSSMAAAGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD02-01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACGGACGGGAGCTCTGGGGCCAACGTCCTGACCTTCGGGGCC	CSATDGSSGANVLTF	In	VDJ	1	27	0.00362367467454033	0.004508265152780097	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	4	8	2	22	4	22	26	36	46	40	68		TCRBV20-01,TCRBV20-or09_02												CSATDGSSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD02-01*02	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCSRGGGACTYRGCTGTGTATYTYTGTGCCAGCAGCCAAGATAACAGGGGCCCCTACGAGCAGTACTTCGGGCCG	CASSQDNRGPYEQYF	In	VDJ	1	27	0.00362367467454033	0.004508265152780097	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	2	2	7	2	22	34	48	41	50	TCRBV07,TCRBV12													CASSQDNRGPYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCCAACTCCCATCAGGGGGCCTGACTACGAGCAGTACTTCGGGCCG	CASSPTPIRGPDYEQYF	In	VDJ	1	28	0.0037578848476714534	0.0046752379362163966	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	3	11	4	26	38	57	49	61		TCRBV12-03,TCRBV12-04												CASSPTPIRGPDYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCGTTGCCTCGACAGGGCTCGAGACCCAGTACTTCGGGCCA	CASSVASTGLETQYF	In	VDJ	1	28	0.0037578848476714534	0.0046752379362163966	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	3	5	8	3	22	34	49	42	52	TCRBV07,TCRBV11													CASSVASTGLETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGACAACACTAGCGCAGGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	29	0.003892095020802577		44	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	3	6	2	7	4	26	34	48	41	52		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATTGGGGTTCTCTAACTATGGCTACACCTTCGGTTCG	CSARLGFSNYGYTF	In	VDJ	1	29	0.003892095020802577	0.004842210719652696	42	TCRBV20						TCRBJ01	TCRBJ01-02	01	2	6	2	0	2	4	26	38	44	40	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARLGFSNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGTAGGGGACAGGGACCTGAAGCTTTCTTTGGACAA	CASSRGQGPEAFF	In	VDJ	1	30	0.0040263051939337	0.005009183503088996	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	3	6	2	2	22	34	45	36	47	TCRBV12,TCRBV21													CASSRGQGPEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAAGACTCRGCCSTGTATSTCTGYGCCAGCAGTCAGCAACAGGGCCCCGCGTCCAAGCAGCACTTCGGGCCG	CASSQQQGPASKQHF	In	VDJ	1	31	0.004160515367064824	0.005176156286525296	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	3	14	6	17	18	29	41	35	58	TCRBV04,TCRBV11													CASSQQQGPASKQHF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACKCRGCCRTGTAYSTSTGTGCCAGCAGCCATAGGAGGGGTAACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	0.004294725540195947		43	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	10	0	2	4	4	18	30	40	34	44	TCRBV11,TCRBV15													X+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTRTGTAYCTCTRTGCCAGCAGTGGTACGGGACAGGGCAACTATGGCTACACCTTCGGTTCG	XASSGTGQGNYGYTF	In	VDJ	1	33	0.00442893571332707	0.0055101018533978965	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	3	2	5	1	25	37	51	42	52	TCRBV26,TCRBV28													XASSGTGQGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCACCCGGGACAGCTCGAACACTGAAGCTTTCTTTGGACAA	CASSTRDSSNTEAFF	In	VDJ	1	33	0.00442893571332707	0.0055101018533978965	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	1	4	3	18	30	41	34	44	TCRBV07,TCRBV11													CASSTRDSSNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGGGGACTCCCCTCTCCGGAAACACCATATATTTTGGAGAG	CASRGTPLSGNTIYF	In	VDJ	1	34	0.0045631458864581935	0.005677074636834196	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	6	0	10	4	1	9	26	37	44	38	53		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASRGTPLSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCCGGGGGGGTCGGCTACGAGCAGTACTTCGGGCCG	CATSAGGVGYEQYF	In	VDJ	1	34	0.0045631458864581935	0.005677074636834196	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	8	0	3	1	4	24	37	46	38	50		TCRBV24-01,TCRBV24-or09_02												CATSAGGVGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTCGGGGGGGCCCCCACAGATACGCAGTATTTTGGCCCA	CASSFGGAPTDTQYF	In	VDJ	1	34	0.0045631458864581935	0.005677074636834196	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	8	0	2	0	4	18	-1	40	32	44	TCRBV07,TCRBV11													CASSFGGAPTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTCACCCTGATTAACCGATGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	35	0.004697356059589317		52	unresolved						TCRBJ01	TCRBJ01-02	01	5	2	7	4	22	0	23	34	-1	56	59	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCCCAGACAGGTAATGAGCAGTTCTTCGGGCCA	CATSAQTGNEQFF	In	VDJ	1	36	0.00483156623272044	0.006011020203706796	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	4	7	4	1	24	37	47	41	48		TCRBV24-01,TCRBV24-or09_02												CATSAQTGNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGGGCAGGGGTTAGCTACGAGCAGTACTTCGGGCCG	CASRAGVSYEQYF	In	VDJ	1	36	0.00483156623272044	0.006011020203706796	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	2	3	2	4	23	34	42	36	46	TCRBV09,TCRBV12													CASRAGVSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGAAGCGCAGGGGGCAGAGTCACCCCTCCACTTTGGGAAC	CASSEAQGAESPLHF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	4	0	10	6	4	26	38	52	44	56		TCRBV12-03,TCRBV12-04												CASSEAQGAESPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD01-01*01	TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCGACAGGGGGTCAGGAGACCCAGTACTTCGGGCCA	CSAPTGGQETQYF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	1	5	2	4	26	35	46	37	50		TCRBV20-01,TCRBV20-or09_02												CSAPTGGQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCCCTCACCGGGGAGGGCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	38	0.005099986578982687		44	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	9	0	6	8	0	18	30	-1	38	45	TCRBV07,TCRBV11													X+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCTGAGGACTAGCGGGGGACCACCAGGGACCCAGTACTTCGGGCCA	CASSLRTSGGPPGTQYF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	51	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	1	2	7	5	9	26	37	55	42	64		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSLRTSGGPPGTQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCCCCCGATGCGGGGGAAGAGACCCAGTACTTCGGGCCA	CSASAPDAGEETQYF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	7	2	3	10	0	26	37	-1	47	54		TCRBV20-01,TCRBV20-or09_02												CSASAPDAGEETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAAGGTGGCAGGGAACGTGGCTACACCTTCGGTTCG	CATSEGGRERGYTF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	3	7	6	4	24	38	49	44	53		TCRBV24-01,TCRBV24-or09_02												CATSEGGRERGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCCCGGACAGGGTTAATGGCTACACCTTCGGTTCG	CASSPDRVNGYTF	In	VDJ	1	42	0.00563682727150718	0.007012856904324595	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	1	3	6	3	3	24	35	46	38	49		TCRBV24-01,TCRBV24-or09_02												CASSPDRVNGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCCATCTATCCGGCAGGCCCATTCACCCCTCCACTTTGGGAAC	XASSPSIRQAHSPLHF	In	VDJ	1	42	0.00563682727150718	0.007012856904324595	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	4	4	8	12	3	22	34	50	46	53	TCRBV04,TCRBV07,TCRBV17													XASSPSIRQAHSPLHF+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGATTCCAGCGGGGGGTCGGAGACCCAGTACTTCGGGCCA	CASSQDSSGGSETQYF	In	VDJ	1	44	0.0059052476177694265	0.0073468024711971945	48				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	6	1	5	4	3	18	35	48	39	51	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQDSSGGSETQYF+X+TCRBJ02-05		TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGACAGGATACCGTGAAGCTTTCTTTGGACAA	CASSQGTGYREAFF	In	VDJ	1	45	0.006039457790900551	0.007513775254633495	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	1	4	7	0	6	26	-1	49	42	55		TCRBV03-01,TCRBV03-02												CASSQGTGYREAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAAGGGAGAACACTGAAGCTTTCTTTGGACAA	CSARENTEAFF	In	VDJ	1	45	0.006039457790900551	0.007513775254633495	33	TCRBV20						TCRBJ01	TCRBJ01-01	01	6	0	8	1	2	0	26	34	-1	36	40		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARENTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGGCCGGGGGGCCGGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASRPGGRATNEKLFF	In	VDJ	1	46	0.006173667964031674	0.007680748038069795	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	6	8	1	0	2	5	23	34	43	36	48	TCRBV06,TCRBV10													CASRPGGRATNEKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01*01	TCRBJ01-04*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTGTAGACGGCGAAGCTTTCTTTGGACAA	CASSVDGEAFF	In	VDJ	1	49	0.0065762984834250434	0.008181666388378694	33	TCRBV03						TCRBJ01	TCRBJ01-01	01	6	2	7	8	4	3	26	37	44	41	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVDGEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CRRRRGACTCAGCCSTGTATCTCTRCACCAGCAGCCAAGGAGTAGGGGAGGGTCAAGAGACCCAGTACTTCGGGCCA	XTSSQGVGEGQETQYF	In	VDJ	1	49	0.0065762984834250434	0.008181666388378694	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	9	0	2	6	1	23	39	52	45	53	TCRBV04,TCRBV17													XTSSQGVGEGQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAGGCAGGGTATTTCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	51	0.006844718829687291		47	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	5	3	13	26	38	46	41	59		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAGGGGTTATCCTTTCAATTCGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	52	0.006978929002818414		49	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	5	2	4	0	16	26	-1	43	38	59		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGCCCGGCGGCCARCCCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPAAXPGANVLTF	In	VDJ	1	54	0.00724734934908066	0.009016530305560193	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	5	7	5	2	3	6	24	36	43	39	49	TCRBV12,TCRBV21					01,02								CASSPAAXPGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCCCAGGACTATGACTACACCTTCGGTTCG	CATSAQDYDYTF	In	VDJ	1	55	0.007381559522211784	0.009183503088996493	36	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	1	9	10	4	3	24	37	47	41	50		TCRBV24-01,TCRBV24-or09_02				01,02								CATSAQDYDYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD02-01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGGAGGGCGGGAAGGTGGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	66	0.00885787142665414		55	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	7	3	0	7	6	26	40	53	47	59		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCGGACAGGGGAAATTCACCCCTCCACTTTGGGAAC	CSARPDRGNSPLHF	In	VDJ	2	73	0.009797342638572003	0.012189013190849892	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	1	2	7	2	1	26	38	49	40	50		TCRBV20-01,TCRBV20-or09_02												CSARPDRGNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTAAGGAACTCCCATTTCTTTCTTGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	93	0.01248154610119447		50	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	3	10	5	2	14	26	42	47	44	61		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTATTTACCGGGGCCGGGGAGCTGTTTTTTGGAGAA	CSVFTGAGELFF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	6	8	3	6	6	0	25	33	-1	39	44													Vb 4	CSVFTGAGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGGGACGTAGCGGGGAATCTGGAGGGGAGCTGTTTTTGGAGAA		Out	VDJ	1	36	0.00483156623272044		44	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	6	5	3	18	6	17	25	33	47	39	64													Vb 4	X+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGCTCCTCAGGGCTTGGGGTTACCCAGTACTTCGGGCCA	YASSSSGLGVTQYF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	42	TCRBV26	TCRBV26-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	4	3	8	5	9	27	38	48	43	57														YASSSSGLGVTQYF+TCRBV26-01+TCRBJ02-05	TCRBV26-01*01	TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTGTGTATCTCTATGTCACCGGCTCTCGGGCAGAAAATTCACCCCTCCACTTTGGGAAC	YVTGSRAENSPLHF	In	VDJ	1	30	0.0040263051939337	0.005009183503088996	42	TCRBV26	TCRBV26-01	01				TCRBJ01	TCRBJ01-06	01	13	8	0	7	12	4	27	31	47	43	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									YVTGSRAENSPLHF+TCRBV26-01+TCRBJ01-06	TCRBV26-01*01		TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTCACGACAGTAGCCTTAATGAAAAACTGTTTTTTGGCAGT	YASSHDSSLNEKLFF	In	VDJ	1	48	0.00644208831029392	0.008014693604942395	45	TCRBV26	TCRBV26-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	2	5	4	3	6	27	39	47	42	53														YASSHDSSLNEKLFF+TCRBV26-01+TCRBJ01-04	TCRBV26-01*01	TCRBD01-01*01	TCRBJ01-04*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTATCGGATCAACGGACGGGGTTGGCTACACCTTCGGTTCG	YASSIGSTDGVGYTF	In	VDJ	1	49	0.0065762984834250434	0.008181666388378694	45	TCRBV26	TCRBV26-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	8	3	7	14	1	27	39	58	53	59														YASSIGSTDGVGYTF+TCRBV26-01+TCRBJ01-02	TCRBV26-01*01	TCRBD02-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTTGGGGAGCCGGGGAGCTGTTTTTTGGAGAA	YASSWGAGELFF	In	VDJ	1	52	0.006978929002818414	0.008682584738687594	36	TCRBV26	TCRBV26-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	9	2	6	1	0	27	40	-1	41	46														YASSWGAGELFF+TCRBV26-01+TCRBJ02-02	TCRBV26-01*01	TCRBD02-01*02	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCGTGGGTGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSVGGSGANVLTF	In	VDJ	1	16	0.0021473627700979736	0.0026715645349807983	45	TCRBV11	unresolved					TCRBJ02	TCRBJ02-06	01	5	0	9	0	2	3	18	30	35	32	38		TCRBV11-01,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVGGSGANVLTF+TCRBV11-X+TCRBJ02-06	unresolved		TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGCCCGGCCGGGACAGCTAAACACTGAAGCTTTCTTTGGACAA	CASSARPGQLNTEAFF	In	VDJ	1	18	0.00241578311636022	0.003005510101853398	48	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	2	8	3	26	38	53	46	56		TCRBV06-07,TCRBV06-08												CASSARPGQLNTEAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TGTRTATTTCTGCGCCAGCAGTGAGTCCTTGTACTTGTTAACTAGCGGACCACCCACAGATACGCAGTATTTTGGCCCA	CASSESLYLLTSGPPTDTQYF	In	VDJ	1	21	0.00281841363575359	0.0035064284521622974	63	TCRBV10	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	3	5	2	13	6	10	27	48	40	54		TCRBV10-01,TCRBV10-02				01,02								CASSESLYLLTSGPPTDTQYF+TCRBV10-X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCCCAGACATCTGTRTACTTSTGTGCCAGCAGTTACCAGTCGGACAGGAACACTGAAGCTTTCTTTGGACAA	CASSYQSDRNTEAFF	In	VDJ	1	30	0.0040263051939337	0.005009183503088996	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	1	5	1	5	0	23	38	-1	43	49		TCRBV06-08,TCRBV06-09												CASSYQSDRNTEAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGGSGACTYGGCTGTGTATCTCTGTGCCAGCAGCTCGGCGACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSATGANVLTF	In	VDJ	1	34	0.0045631458864581935	0.005677074636834196	42	TCRBV07	unresolved					TCRBJ02	TCRBJ02-06	01	3	9	0	2	1	2	19	32	36	33	38		TCRBV07-01,TCRBV07-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSATGANVLTF+TCRBV07-X+TCRBJ02-06	unresolved		TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TGTACCCTCTCAGACATCTGTGTACTTCTGTGCCAGCAGTGGCAGGTGCTGAAAGACCTATGGCTACACCTTCGGTTCG	CASSGRC*KTYGYTF	Stop	VDJ	1	20	0.002684203462622467		45	TCRBV06	TCRBV06-04		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	4	4	1	11	28	41	46	42	57			01,02											CASSGRC*KTYGYTF+TCRBV06-04+TCRBJ01-02	TCRBV06-04	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTAGAACAGGGGGCGCCCCCGGCGAGCAGTACTTCGGGCCG	CASSRTGGAPGEQYF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	45	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	0	6	3	8	26	38	50	41	58														CASSRTGGAPGEQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCATCAGTGAGTGGGGCGGCTACAATGAGCAGTTCTTCGGGCCA	CAISEWGGYNEQFF	In	VDJ	1	17	0.0022815729432290968	0.002838537318417098	42	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	7	0	3	4	2	26	38	47	42	49														CAISEWGGYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTCAACACTTACAGGGGTGGCAGTACTTCGGGCCG	CASSQHLQGWQYF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	39	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	2	9	8	2	26	38	53	46	55														CASSQHLQGWQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGAAGCGGGAAGGGGGTTGGACTATGGCTACACCTTCGGTTCG	CASSEAGRGLDYGYTF	In	VDJ	1	55	0.007381559522211784	0.009183503088996493	48	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	5	6	3	3	2	10	26	38	47	40	57														CASSEAGRGLDYGYTF+TCRBV06-07+TCRBJ01-02	TCRBV06-07*01	TCRBD02-01*02	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAACCAGGGGGCCAACGAGCAGTACTTCGGGCCG	CASNQGANEQYF	In	VDJ	1	60	0.0080526103878674	0.010018367006177992	36	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	4	0	5	2	2	26	36	46	38	48														CASNQGANEQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTGCGAGGACAGGGAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	17	0.0022815729432290968		46	TCRBV07	TCRBV07-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	3	1	4	1	19	33	45	37	46														X+TCRBV07-07+TCRBJ01-01	TCRBV07-07*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
TGTATTTTTGTGCCAGCAGCCACCGGGGCCGGACGCAGCTAGGAGCTCCTATAATTCACTCCTCCACTTTGGGAAC		Out	VDJ	1	22	0.0029526238088847133		62	TCRBV16	TCRBV16-01					TCRBJ01	TCRBJ01-06	01	3	7	0	15	2	31	8	22	29	24	60			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV16-01+TCRBJ01-06	TCRBV16-01		TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCTCAATAGGTCAGCCCCAGCATTTTGGTGAT	CASSSIGQPQHF	In	VDJ	1	35	0.004697356059589317	0.005844047420270496	36	TCRBV16	TCRBV16-01					TCRBJ01	TCRBJ01-05	01	5	5	4	6	5	0	29	41	-1	46	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSIGQPQHF+TCRBV16-01+TCRBJ01-05	TCRBV16-01		TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAACACTGGACAGGAACCTACGAGCAGTACTTCGGGCCG	CASSQHWTGTYEQYF	In	VDJ	1	22	0.0029526238088847133	0.0036734012355985972	45	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	4	2	4	2	23	38	49	42	51													Vb 7.1	CASSQHWTGTYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCAAGATGCGGGGGACGAGCAGTACTTCGGGCCG	XASSQDAGDEQYF	In	VDJ	1	26	0.003489464501409207	0.004341292369343797	39	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	7	2	5	1	0	22	39	-1	40	47													Vb 7.1	XASSQDAGDEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD02-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAGGCCCGGGGCAGCTATGGCTACACCTTCGGTTCG	CASSQARGSYGYTF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	42	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-02	01	3	7	0	4	5	2	23	37	47	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	CASSQARGSYGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTTAGCAAGGTGGTCACCCCTCCACTTTGGGAAC	CASSLARWSPLHF	In	VDJ	1	19	0.0025499932894913436	0.003172482885289698	39	TCRBV12	TCRBV12-01	01				TCRBJ01	TCRBJ01-06	01	3	5	4	10	4	3	22	36	43	40	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLARWSPLHF+TCRBV12-01+TCRBJ01-06	TCRBV12-01*01		TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCCAAGAAAAGGGACTTCCTGGCATCTACAATGAGCAGTTCTTCGGGCCA	CASSQEKGLPGIYNEQFF	In	VDJ	1	40	0.005368406925244934	0.006678911337451995	54	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	10	3	8	9	22	34	48	42	57						01,02								CASSQEKGLPGIYNEQFF+TCRBV12-01+TCRBJ02-01	TCRBV12-01*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACGAGATACTAGCACAGATACGCAGTATTTTGGCCCA	CATSRRDTSTDTQYF	In	VDJ	1	27	0.00362367467454033	0.004508265152780097	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	3	10	0	6	0	18	33	-1	39	42						01,02								CATSRRDTSTDTQYF+TCRBV15-01+TCRBJ02-03	TCRBV15-01*01	TCRBD02-01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATTCAGGCCAGAACACTGAAGCTTTCTTTGGACAA	CATSRDSGQNTEAFF	In	VDJ	1	55	0.007381559522211784	0.009183503088996493	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	4	1	2	3	18	35	41	37	44														CATSRDSGQNTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACGCAGCCATGTACCTGTGTGCCACCGCTGGGCGCAGTGGGACCGGGGAGCTGTTTTTTGGAGAA	CATAGRSGTGELFF	In	VDJ	2	79	0.010602603677358744	0.01319084989146769	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	8	8	0	5	3	8	18	27	34	30	42														CATAGRSGTGELFF+TCRBV15-01+TCRBJ02-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTACCCAGGGGTTCCAAAACATTCAGTACTTCGGCGCC	CASSLTQGFQNIQYF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	4	2	5	6	4	18	30	42	36	46														CASSLTQGFQNIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-04*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCAACGGATGAACACTGAAGCTTTCTTTGGACAA	CASSLQRMNTEAFF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	3	1	8	0	5	0	18	32	-1	37	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLQRMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGAGAGGGACTACCAATCAGCCCCAGCATTTTGGTGAT	CASSPRGTTNQPQHF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	0	9	3	6	1	18	30	43	36	44						01,02								CASSPRGTTNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01	TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGACAGGGGTACCTATGGCTACACCTTCGGTTCG	CASSLDRGTYGYTF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	2	4	0	3	18	-1	41	35	44														CASSLDRGTYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCGTACTCTTACCCACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CASSAYSYPQSRANVLTF	In	VDJ	1	17	0.0022815729432290968	0.002838537318417098	54	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	5	3	6	5	14	5	18	30	47	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAYSYPQSRANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTTCTGGGCGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	17	0.0022815729432290968		43	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	4	8	0	1	5	2	18	31	40	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGCGGGGACAGGGGAACTATGGCTACACCTTCGGTTCG	CASSWRGQGNYGYTF	In	VDJ	1	17	0.0022815729432290968	0.002838537318417098	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	2	2	4	0	18	31	-1	35	45														CASSWRGQGNYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGACCCCTGGGACGAACACTGAAGCTTTCTTTGGACAA	CASSLTPGTNTEAFF	In	VDJ	1	22	0.0029526238088847133	0.0036734012355985972	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	0	7	1	9	0	18	30	-1	39	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTPGTNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGGAGGGACTAGCGGGTTCCTACGAGCAGTACTTCGGGCCG	CASSQEGLAGSYEQYF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	4	1	5	1	18	30	47	35	48						01,02								CASSQEGLAGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGACAGGTGGGAACACTGAAGCTTTCTTTGGACAA	CASSPTGGNTEAFF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	4	1	2	3	18	30	38	32	41														CASSPTGGNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGATGTTCCAAGTCGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	30	0.0040263051939337		46	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	6	2	7	4	16	0	18	29	-1	45	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTCGCGCGTTGGGACAGTCGTCCGAGCAGTACTTCGGGCCG	CASSFRALGQSSEQYF	In	VDJ	1	30	0.0040263051939337	0.005009183503088996	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	5	6	9	5	18	32	48	41	53														CASSFRALGQSSEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGACTCGTCGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSRDSSSSYEQYF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	10	0	1	7	18	30	37	31	44						01,02								CASSRDSSSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCCACTTGTCAGGGGACTTTATGGCTACACCTTCGGTTCG	CASSLPLVRGLYGYTF	In	VDJ	1	37	0.004965776405851563	0.006177992987143096	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	3	4	2	5	9	4	18	32	47	41	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLPLVRGLYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAGTGCTGGTAGGCTGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	38	0.005099986578982687		55	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	14	5	18	30	48	44	53														X+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAAAGGGTCGGCTGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	42	0.00563682727150718		53	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	5	2	6	5	12	5	18	30	46	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGTCCGTGTTGGGTAATTCACCCCTCCACTTTGGGAAC	CASSPSVLGNSPLHF	In	VDJ	1	52	0.006978929002818414	0.008682584738687594	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-06	01	5	0	9	6	11	0	18	30	-1	41	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSVLGNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01		TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAATTAACCTCAGGGGGAGAGTGAGACCCAGTACTTCGGGCCA	CAN*PQGESETQYF	Stop	VDJ	1	31	0.004160515367064824		42	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	12	4	1	5	10	5	26	31	48	41	53														CAN*PQGESETQYF+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTACCTGCCCCGGGTTCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	97	0.013018386793718964		47	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	4	7	8	2	26	43	55	51	57						01,02								X+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATCGCGCGGCAGGGGGTGAAGCTTTCTTTGGACAA	CASSQDRAAGGEAFF	In	VDJ	1	23	0.003086833982015837	0.0038403740190348975	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	1	7	10	0	20	35	-1	45	52														CASSQDRAAGGEAFF+TCRBV23-01+TCRBJ01-01	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCTTACAGGGACGGAAATTAACACAGATACGCAGTATTTTGGCCCA	CASSLTGTEINTDTQYF	In	VDJ	1	25	0.0033552543282780833	0.004174319585907497	51	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	3	3	2	4	11	20	31	41	35	52														CASSLTGTEINTDTQYF+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCACCCGGGCCCTTGTGGTTCGGTGGGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	0.004294725540195947		49	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-07	01	3	8	0	7	3	16	20	34	41	37	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01		TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGGGACTAGCGGGTACTACAATGAGCAGTTCTTCGGGCCA	CASSQGTSGYYNEQFF	In	VDJ	1	54	0.00724734934908066	0.009016530305560193	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	0	4	3	0	2	20	-1	47	35	49						01,02								CASSQGTSGYYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGGAGCGGGGAGACTCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	83	0.011139444369883237		47	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	6	3	1	2	5	20	34	43	36	48														X+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATCCTGGGCGGTCAATCAGCCCCAGCATTTTGGTGAT	CASRSWAVNQPQHF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	6	8	0	3	5	3	23	34	43	39	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRSWAVNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCTCGACTAGCGGGAGGGTTGGTGAGCAGTTCTTCGGGCCA	CASSTSTSGRVGEQFF	In	VDJ	1	13	0.0017447322507046035	0.0021706461846718985	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	2	0	9	5	4	23	35	54	40	58														CASSTSTSGRVGEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAGTGGACGGTTCAGGGCCCCAGCATTTTGGTGAT	CASRVDGSGPQHF	In	VDJ	1	14	0.0018789424238357267	0.0023376189681081983	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	6	1	7	9	3	8	23	34	41	37	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRVDGSGPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCGGATCTATACTCTCTAGCACAGATACGCAGTATTTTGGCCCA	CASSTGSILSSTDTQYF	In	VDJ	1	15	0.00201315259696685	0.002504591751544498	51	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-03	01	5	1	8	0	3	12	23	35	41	38	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTGSILSSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01		TCRBJ02-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGGACTAGCGATTACAATGAGCAGTTCTTCGGGCCA	CASSRTSDYNEQFF	In	VDJ	1	20	0.002684203462622467	0.0033394556687259976	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	1	6	4	2	2	23	34	45	36	47						01,02								CASSRTSDYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATTCCCTCGGTACGGGTCCCACTGGGGAGACCCAGTACTTCGGGCCA	CASSYSLGTGPTGETQYF	In	VDJ	1	20	0.002684203462622467	0.0033394556687259976	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	8	4	5	11	10	23	37	52	48	62						01,02								CASSYSLGTGPTGETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCCCCGGGCAGCCGTCCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	23	0.003086833982015837		43	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	8	8	0	0	4	7	23	32	40	36	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCAGAATCGGCTGCCTTAAGGGGCTACACCTTCGGTTCG	CASSYSESAALRGYTF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	0	5	4	8	16	0	23	40	-1	56	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSESAALRGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCCCCCACGGTGAGCAGTTCTTCGGGCCA	CASSFPHGEQFF	In	VDJ	1	24	0.00322104415514696	0.004007346802471197	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	8	5	9	7	0	23	36	-1	43	46						01,02								CASSFPHGEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTAGGGATCCGGGACAGGGTGCCGAGCAGTACTTCGGGCCG	CASSRDPGQGAEQYF	In	VDJ	1	27	0.00362367467454033	0.004508265152780097	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	6	8	3	23	35	52	43	55														CASSRDPGQGAEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCTGTCGGGGGGGCTTACAATGAGCAGTTCTTCGGGCCA	CASSSVGGAYNEQFF	In	VDJ	1	29	0.003892095020802577	0.004842210719652696	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	8	0	4	4	2	23	36	48	40	50														CASSSVGGAYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCACGGTACCTACGAGCAGTACTTCGGGCCG	CASSDHGTYEQYF	In	VDJ	1	33	0.00442893571332707	0.0055101018533978965	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	2	7	2	0	7	23	-1	38	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDHGTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATTAACCGGGACAGGGGGCACGAATGAGCAGTTCTTCGGGCCA	CASRLTGTGGTNEQFF	In	VDJ	1	36	0.00483156623272044	0.006011020203706796	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	0	7	7	3	23	34	53	41	56														CASRLTGTGGTNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCTTGGCGGGAGGGCGGAGGGAGACCCAGTACTTCGGGCCA	CASSFLAGGRRETQYF	In	VDJ	1	36	0.00483156623272044	0.006011020203706796	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	7	0	5	5	6	23	36	50	41	56														CASSFLAGGRRETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAATACGGGACAGACGAACACTGAAGCTTTCTTTGGACAA	CASNTGQTNTEAFF	In	VDJ	1	38	0.005099986578982687	0.006344965770579396	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	0	5	1	4	2	23	33	44	37	46														CASNTGQTNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAGGTTACAGGGGGCCAAAACATTCAGTACTTCGGCGCC	CASKVTGGQNIQYF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	7	3	0	5	5	1	23	33	47	38	48														CASKVTGGQNIQYF+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-04*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCTCGGGACAGGGGGCAACGAGCAGTACTTCGGGCCG	CASSLGTGGNEQYF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	0	5	3	1	23	35	50	38	51														CASSLGTGGNEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGGCTCCCCGGGAGGACTGAAGCTTTCTTTGGACAA	CASRLPGRTEAFF	In	VDJ	1	43	0.005771037444638303	0.007179829687760895	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	8	8	1	5	8	0	23	32	-1	40	47														CASRLPGRTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCAGCTAGCGGGAGCCAATGAGCAGTTCTTCGGGCCA	CASSYQLAGANEQFF	In	VDJ	1	66	0.00885787142665414	0.011020203706795793	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	4	2	6	3	1	23	38	51	41	52														CASSYQLAGANEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCATCGGTCGGAGAACACTGAAGCTTTCTTTGGACAA	CASSHRSENTEAFF	In	VDJ	1	67	0.008992081599785264	0.011187176490232093	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	5	1	8	1	8	0	23	35	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHRSENTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCTGACAGTGCCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	14	0.0018789424238357267		49	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	3	2	5	0	2	3	24	38	45	40	48													Vb 18	X+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGCAGGGACAGACCTACGAACAGTACTTCGGGCCG	CASSQGQTYEQYF	In	VDJ	1	20	0.002684203462622467	0.0033394556687259976	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	10	3	9	24	35	45	38	54													Vb 18	CASSQGQTYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCCCCTCCAGAAACAGAGACACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	24	0.00322104415514696		50	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	5	3	11	4	24	38	53	49	57													Vb 18	X+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCACCCAACAGGGGGCAGGTAACGAGCAGTACTTCGGGCCG	CATQQGAGNEQYF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	3	0	5	4	5	24	31	44	35	49													Vb 18	CATQQGAGNEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGAACAAGGGCTCCAATATGGCTACACCTTCGGTTCG	CASSPEQGLQYGYTF	In	VDJ	1	41	0.005502617098376057	0.006845884120888295	45	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	3	5	3	5	6	6	24	38	48	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPEQGLQYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGAAGGCAACGTCCTGACTTTCGGGGCC	CASSPEGNVLTF	In	VDJ	1	49	0.0065762984834250434	0.008181666388378694	36	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-06	01	3	1	8	9	0	3	24	-1	41	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPEGNVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01		TCRBJ02-06*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCCCCGCAATCAGCCCCAGCATTTTGGTGAT	CASSPRNQPQHF	In	VJ	1	56	0.007515769695342907	0.009350475872432793	36	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-05	01	6	0	0	2	0	5	24	-1	35	-1	40													Vb 18	CASSPRNQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01		TCRBJ01-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGTCCGAAGGGGTCGGGGAGCTGTTTTTTGGAGAA	CASSPSEGVGELFF	In	VDJ	1	67	0.008992081599785264	0.011187176490232093	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	5	2	7	6	1	24	38	49	44	50													Vb 18	CASSPSEGVGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-02*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCGTCGGGGGACTACCTGGAGACCCAGTACTTCGGGCCA	CASGDYLETQYF	In	VDJ	1	72	0.00966313246544088	0.012022040407413592	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	12	0	9	5	5	4	24	29	41	34	45						01,02							Vb 18	CASGDYLETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01	TCRBJ02-05*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTGGAGGGACGTTGGAAACACCATATATTTTGGAGAG	CASWRDVGNTIYF	In	VDJ	3	123	0.016507851295128172	0.020537652362664884	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	7	10	0	3	0	4	24	-1	40	34	44													Vb 18	CASWRDVGNTIYF+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-03*01	2945A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				224	180	38	5	0	204	162	36	6	0	7451	5989	1284	178	0	0.040102195	7.045506	0.0371660665	7.3872714				141	1.18465292	0.0535982624	0.0430814661	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:39:04	Age (Range):45-65 Years (Late Adulthood),Age:58 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 0,overall survival (days):overall survival (days) 2021,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 2118,type of chemo:carbo/taxol	0.8035714066689469	MSKCC- Snyder- P01-02		167.0	
